Clinical Trials Logo

Allergic Contact Dermatitis clinical trials

View clinical trials related to Allergic Contact Dermatitis.

Filter by:

NCT ID: NCT06351449 Not yet recruiting - Clinical trials for Allergic Contact Dermatitis

Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool

PatchCam
Start date: April 15, 2024
Phase:
Study type: Observational

Contact dermatitis (CD) is a common inflammatory skin disease, affecting approximately 15-20% of the general population in industrialized countries and ranking first among occupational diseases in many European countries. The patch test method aims at reproducing the eczematous lesions by applying occlusive patches containing the suspected allergens to the patient's healthy skin. It requires experienced medical staff to read the reaction. Newtones Technologies society has developed a new tool, the SkinCam®, able to capture high resolution cross and parallel images, allowing a quantification of color and relief of skin. This study aims to illustrate patch test results, describing skin appearance (color, roughness, shine), using photographs taken by the SkinCam®.

NCT ID: NCT06191627 Recruiting - Clinical trials for Allergic Contact Dermatitis

Patient Experience and Quality of Patch Testing on the Legs vs Back

Start date: March 4, 2024
Phase: N/A
Study type: Interventional

The gold standard for the diagnosis of allergic contact dermatitis is patch testing, during which allergens are affixed to the skin underneath tape and left for multiple days. A large area of clear skin is thus required for successful testing. While the back is traditionally thought to be the ideal area for testing, the thighs may be more available or advantageous. This study seeks to randomize patients undergoing patch testing to have patches placed on the back or the thighs. The investigators seek to understand the benefits of testing on the legs versus the back in terms of patient experience as well as achieving a successful test. This study will measure patient experience using a survey administered to patients. Quality of testing will be assessed by study coordinators prior the removal of patches.

NCT ID: NCT05991674 Recruiting - Clinical trials for Allergic Contact Dermatitis

A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques

Start date: June 30, 2023
Phase:
Study type: Observational

The goal of this study is to look into the patterns of sensitization to figure out how allergic contact dermatitis (ACD), individual susceptibility, and patient characteristics are connected. The joint application of classic statistics and machine learning methods will reveal the relationship between contact dermatitis expressions and several clinical characteristics.

NCT ID: NCT05858723 Not yet recruiting - Clinical trials for Allergic Contact Dermatitis

Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool

Start date: August 2023
Phase: N/A
Study type: Interventional

Linalool is currently one of the most used fragrance substances in cosmetic and household products. Previous studies report a high prevalence (5.9-11.7%) of contact allergy to hydroperoxides of linalool (Lin-OOH)1.0% in pet. among patch tested patients. The optimal test concentration of Lin-OOH in patch tests is not known and requires further investigation. It is of great importance to establish the optimal test concentration and elicitation threshold of Lin-OOH to improve diagnosis and prevent development of Allergic Contact Dermatitis (ACD). We want to mimic real-life exposure to Lin-OOH, by conducting a ROAT (Repeated Open Application Test) study, on 40 adult participants (20 patients with confirmed contact allergy to Lin-OOH, and 20 healthy participants) to low doses of Lin-OOH using a simulated "perfume", during a maximum of 21 days of exposure. With this knowledge, we aim to: 1. Establish the optimal patch test concentration to diagnose ACD to Lin-OOH 2. In case of confirmed contact allergy, examine the threshold value for the development of ACD upon daily exposure to a simulated leave-on cosmetic product

NCT ID: NCT05535738 Recruiting - Clinical trials for Allergic Contact Dermatitis

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Start date: November 15, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.

NCT ID: NCT05498467 Not yet recruiting - Clinical trials for Allergic Contact Dermatitis

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

NCT ID: NCT05339750 Completed - Clinical trials for Allergic Contact Dermatitis

Allergy Skin Patch Artificial Intelligence (AI)

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.

NCT ID: NCT04365140 Completed - Clinical trials for Allergic Contact Dermatitis

MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel

Start date: March 1, 2019
Phase:
Study type: Observational [Patient Registry]

Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.

NCT ID: NCT03945760 Completed - Clinical trials for Allergic Contact Dermatitis

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Start date: September 14, 2020
Phase: Early Phase 1
Study type: Interventional

The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.

NCT ID: NCT03935971 Recruiting - Clinical trials for Allergic Contact Dermatitis

The Effects of Dupilumab on Allergic Contact Dermatitis

Start date: December 18, 2019
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.